{"shortAnswer":"PEG-MGF is in limbo: it is not approved, and it is on neither FDA list for compounding. No pharmacy may lawfully make it. The evidence grade is insufficient: we found no published study of PEG-MGF itself. FDA found no data on any person given it.","url":"https://peptideindex.ai/compound/peg-mgf","status":"limbo","statusCheckedAt":"2026-10-25T23:58:30.000Z","statusStale":false,"regulatoryAsOf":"2026-10-25","verified":"2026-10-26T03:03:29.557Z","primarySourceUrl":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","clinicallyReviewed":false,"notice":"Information, not medical advice.","id":"6b576bcc-d69e-4592-9573-6a15f4b42c35","object":"compound","slug":"peg-mgf","name":"PEG-MGF","attrs":{"name":"PEG-MGF","class":"growth-hormone-axis","access":[{"type":"none","detail":"There is no legal route to PEG-MGF in the US today. FDA lists it as withdrawn from Category 2, and it is not on the list of substances pharmacies may use.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"trials":[],"aliases":["Mechano growth factor pegylated"],"summary":"A lab-made peptide related to IGF-1, a growth signal, with a chemical chain called PEG attached. It is sold online as a research compound.","citations":[{"n":1,"url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2"},{"n":2,"url":"https://www.fda.gov/media/94155/download","tier":"primary","type":"regulatory","title":"FDA: categories of bulk drug substances nominated under section 503A, list updated 14 May 2026"},{"n":3,"url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances used in compounding under section 503A"},{"n":4,"url":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee","tier":"primary","type":"regulatory","title":"FDA: notice of the next Pharmacy Compounding Advisory Committee meeting, no date posted"},{"n":5,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020","tier":"primary","type":"regulatory","title":"FDA warning letter to a compounding pharmacy, 1 April 2020"},{"n":6,"url":"https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution","tier":"primary","type":"regulatory","title":"US Department of Justice: a compounding pharmacy pleads guilty to distributing unapproved drugs, 29 October 2020"},{"n":7,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026","tier":"primary","type":"regulatory","title":"FDA warning letter to a seller of research-use peptides, 24 August 2026"},{"n":8,"url":"https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/","tier":"legal-analysis","type":"legal-analysis","title":"McDermott Will & Schulte: what the July 2026 committee votes on peptides mean"},{"n":9,"url":"https://www.goodwinlaw.com/en/insights/blogs/2026/05/fda-signals-potentially-evolving-stance-toward-compounding-of-certain-peptides","tier":"legal-analysis","type":"legal-analysis","title":"Goodwin: FDA signals a possible change in its stance on compounding some peptides"},{"n":10,"url":"https://www.sheppard.com/insights/blogs/fda-balances-peptide-policy-with-enforcement-against-unlawful-peptide-sellers","tier":"legal-analysis","type":"legal-analysis","title":"Sheppard Mullin: FDA pairs its peptide policy with action against unlawful sellers"},{"n":11,"url":"https://pubmed.ncbi.nlm.nih.gov/17581790/","tier":"peer-reviewed","type":"animal","title":"The MGF E domain in sheep after a heart attack, 2008"},{"n":12,"url":"https://pubmed.ncbi.nlm.nih.gov/25606570/","tier":"peer-reviewed","type":"animal","title":"A lab-made MGF E-domain peptide in mice after a heart attack, 2014"},{"n":13,"url":"https://pubmed.ncbi.nlm.nih.gov/31164836/","tier":"peer-reviewed","type":"animal","title":"MGF in injured mouse muscle, 2019"},{"n":14,"url":"https://pubmed.ncbi.nlm.nih.gov/27334712/","tier":"peer-reviewed","type":"animal","title":"A lab-made MGF E peptide on injured rat Achilles tendon, 2016"},{"n":15,"url":"https://pubmed.ncbi.nlm.nih.gov/19038252/","tier":"peer-reviewed","type":"animal","title":"An MGF gene in mice with an ALS-like disease, 2009"},{"n":16,"url":"https://pubmed.ncbi.nlm.nih.gov/24253050/","tier":"peer-reviewed","type":"in-vitro","title":"The MGF peptide showed no effect on muscle cells in the lab, 2014"},{"n":17,"url":"https://pubmed.ncbi.nlm.nih.gov/26991004/","tier":"peer-reviewed","type":"in-vitro","title":"Full-length MGF and short MGF peptides at the IGF-1 receptor, lab study, 2016"},{"n":18,"url":"https://pubmed.ncbi.nlm.nih.gov/20564425/","tier":"peer-reviewed","type":"in-vitro","title":"MGF in human prostate cancer tissue and cells, lab study, 2010"},{"n":19,"url":"https://pubmed.ncbi.nlm.nih.gov/28035768/","tier":"peer-reviewed","type":"in-vitro","title":"An MGF variant found in seized vials, lab study, 2017"},{"n":20,"url":"https://pubmed.ncbi.nlm.nih.gov/20130113/","tier":"peer-reviewed","type":"reference","title":"Minireview: mechano growth factor and the IGF-1 gene, 2010"},{"n":21,"url":"https://pubmed.ncbi.nlm.nih.gov/42395176/","tier":"peer-reviewed","type":"reference","title":"Review: performance peptides that act on growth hormone and IGF-1, 2026"},{"n":22,"url":"https://www.raps.org/resource/fda-considers-adding-a-dozen-peptides-to-its-bulk-drug-compounding-list.html","tier":"established-news","type":"reference","title":"RAPS: FDA considers adding a dozen peptides to its compounding list"},{"n":23,"url":"https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means","tier":"established-news","type":"reference","title":"Pharmacy Times: a pharmacist on what the peptide category change means, 4 June 2026"}],"known_risks":["FDA warns that PEG-MGF made by a pharmacy may set off the immune system. It may also carry impurities [^1].","FDA found no data on people exposed to PEG-MGF by any route [^1].","In a 2010 lab study, a short MGF peptide made human prostate cancer cells grow [^18]. That peptide was not PEG-MGF, and the study was not in people [^18].","A 2026 review warns that it is uncertain what peptides sold as research compounds contain [^21].","The same review lists harms reported across this group of peptides, such as hormone and blood sugar changes [^21]. It does not tie each harm to PEG-MGF [^21]."],"short_answer":"PEG-MGF is in limbo: it is not approved, and it is on neither FDA list for compounding. No pharmacy may lawfully make it. The evidence grade is insufficient: we found no published study of PEG-MGF itself. FDA found no data on any person given it.","evidence_grade":"insufficient","open_questions":["Nobody knows what PEG-MGF does in people. FDA found no data on any person given it [^1].","We found no published study of PEG-MGF itself. The animal studies cited here used other forms of MGF [^11] [^13].","Whether the short MGF peptide does anything is disputed. Scientists at two drug companies could not repeat its claimed effects on muscle cells [^16].","No natural MGF peptide has been found in cells or tissue, a 2010 review says [^20]. So its role in the body is unclear.","Whether MGF peptides feed cancer growth in people is not known. One lab study raised the concern [^18] [^21].","FDA has not set a date for its committee to meet on PEG-MGF [^4]. Its notice does not say which use the committee will review [^4]."],"section_routes":"There is no legal way to get PEG-MGF in the US today [^1] [^2]. In 2020, FDA said no approved drug contains it [^5]. A pharmacy may use a substance with no official quality standard only if it is in an approved drug or on the federal list [^5]. PEG-MGF is neither, and FDA is still deciding whether to add it [^2] [^4].\n\nAny open trial would appear in the trials block below, with the date the registry was last checked.","regulatory_as_of":"2026-10-25","section_channels":"A 2026 review says PEG-MGF is among peptides sold as \"research compounds\" that people take on their own [^21]. It warns that what such products contain is uncertain [^21]. FDA has warned a seller of research-use peptides that a \"research use only\" label does not stop a product from being a drug [^7]. That letter did not name PEG-MGF [^7].\n\nPharmacies are the other channel a federal record names [^5]. In 2020, FDA warned a compounding pharmacy that its PEG-MGF products did not meet the rules for compounding [^5]. Later that year, the pharmacy pleaded guilty to a federal charge of selling unapproved new drugs, PEG-MGF among them [^6]. FDA warns that PEG-MGF made by a pharmacy may set off the immune system [^1].","section_evidence":"The evidence grade is insufficient: we found no published study of PEG-MGF itself, in people or in animals. FDA found no data on any person given it [^1]. Every study below used a different form of MGF. A study of a related molecule does not show what PEG-MGF does.\n\nAnimal studies of other forms of MGF: in sheep after a heart attack, a piece of MGF kept the heart pumping better than in untreated sheep [^11]. In mice after a heart attack, a lab-made MGF peptide slowed the decline in heart function [^12]. In injured mouse muscle, MGF did not help muscle fibers regrow, but it did reduce scarring [^13]. In rats with an injured Achilles tendon, a lab-made MGF peptide helped the tendon heal [^14]. In mice with a disease like ALS, an MGF gene, not the peptide, helped muscle strength and nerve cell survival [^15]. A result in an animal does not show what happens in people.\n\nLab studies: in 2014, scientists at two drug companies could not repeat the claimed effects of the MGF peptide on muscle cells [^16]. A 2016 lab test found that the short MGF peptides did not switch on the IGF-1 receptor [^17]. A full-length form of MGF did [^17]. A 2010 review says no natural MGF peptide has been found in cells or tissue [^20].\n\nA 2026 review says the claimed muscle and performance benefits of these peptides remain uncertain [^21].","regulatory_status":"limbo","section_what_it_is":"PEG-MGF is a lab-made peptide related to IGF-1, a growth signal in the body [^21]. MGF stands for mechano growth factor [^20]. That name is used for a form of IGF-1 that muscle makes after strain or injury [^20]. It is also used for a short lab-made peptide copied from one end of that form [^20] [^16].\n\nPEG-MGF is MGF with a chemical chain called PEG attached, which is what pegylated means. FDA calls it mechano growth factor pegylated [^1]. Plain MGF, without PEG, is a different substance, and FDA lists it apart [^2].\n\nA 2026 review groups PEG-MGF with peptides sold online as research compounds for muscle and sport [^21]. A US sports drug-testing lab found a different MGF variant in seized vials [^19].","section_is_it_legal":"PEG-MGF is in limbo: FDA lists it as withdrawn from Category 2, and it has not added it to Category 1 [^1] [^2]. That is not approval, and it does not make compounding lawful. Checked 25 October 2026.\n\nCategory 2 is FDA's list of substances that may raise significant safety risks [^1]. Category 1 is the list of substances under review that pharmacies may use while FDA decides [^3]. In April 2026, the groups that nominated PEG-MGF withdrew, so it came off Category 2 [^1] [^8]. Taking a substance off Category 2 does not by itself let pharmacies use it [^8] [^9].\n\nFDA's 503A list of 14 May 2026 names plain MGF, without PEG, in Category 3 [^2]. That category holds substances nominated without enough support [^2]. Plain MGF is a different substance, so its place on the list says nothing about PEG-MGF.\n\nFDA's notice says its Pharmacy Compounding Advisory Committee will discuss PEG-MGF before the end of February 2027 [^4]. The notice gives no exact date and no meeting materials [^4]. Law and trade reports give the same time frame [^8] [^22]. The committee gives advice only. FDA decides by writing a rule [^8].\n\nA June 2026 pharmacy column expected PEG-MGF to stay restricted [^23]. FDA's own page lists it as withdrawn from Category 2 [^1]. The FDA page is what this page follows.\n\nUntil FDA acts, a pharmacy may not use PEG-MGF under the federal compounding law [^3] [^5].","unofficial_channels":[{"type":"research-use-seller","what_it_is":"Websites that sell PEG-MGF as a research compound straight to the public, for people to take on their own.","enforcement":[{"date":"2026-08-24","text":"FDA warning letter to a seller of research-use peptides: a research-use label did not stop its products from being unapproved drugs. The letter does not name PEG-MGF.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026"}],"legal_position":{"text":"FDA says a research-use label does not stop a product meant for people from being a drug. An unapproved new drug may not be sold across state lines.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026"},"documented_risks":[{"text":"A 2026 review warns that it is uncertain what peptides sold as research compounds contain.","source_url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"text":"FDA found no data on people exposed to PEG-MGF by any route.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}]},{"type":"compounding-outside-the-rules","what_it_is":"PEG-MGF made by a pharmacy from a bulk substance that is not on FDA's list.","enforcement":[{"date":"2020-04-01","text":"FDA warning letter to a compounding pharmacy: PEG-MGF was among bulk substances that made its products ineligible under section 503A.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"},{"date":"2020-10-29","text":"Department of Justice: the same pharmacy pleaded guilty to distributing unapproved new drugs, PEG-MGF among them.","source_url":"https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution"}],"legal_position":{"text":"A pharmacy may compound with a substance that has no official standard and is in no approved drug only if it is on FDA's list. FDA said in 2020 that PEG-MGF is not on that list.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"},"documented_risks":[{"text":"FDA warns that PEG-MGF made by a pharmacy may set off the immune system and may carry impurities.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}]}]},"provenance":{"name":{"fact_id":"cd008cf2-56ac-46cd-8e18-714ab866aacb","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-25T23:58:30.019Z","confidence":1,"stale":false},"class":{"fact_id":"cfb7e1a5-c828-479b-9a32-4cd47ebcd42d","source_url":"https://pubmed.ncbi.nlm.nih.gov/42395176/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:57:40.541Z","checked_at":"2026-10-25T23:58:30.022Z","confidence":1,"stale":false},"access":{"fact_id":"691bf25a-dad7-4afc-8552-aec3c2c0314f","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-25T23:58:29.995Z","confidence":1,"stale":false},"trials":{"fact_id":"8c22ca55-6512-48c7-a3b7-d19876891475","source_url":"https://clinicaltrials.gov/api/v2/studies?query.intr=PEG-MGF+OR+pegylated+mechano+growth+factor&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","source_type":"primary","captured_at":"2026-10-25T23:58:35.856Z","checked_at":"2026-10-25T23:58:35.856Z","confidence":1,"stale":false},"aliases":{"fact_id":"032bb733-7b9d-4985-b0e1-4cd9595ece89","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-25T23:58:30.020Z","confidence":1,"stale":false},"summary":{"fact_id":"b28ec5b3-69fe-4858-b9dd-b651f7f2882b","source_url":"https://pubmed.ncbi.nlm.nih.gov/42395176/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:57:40.541Z","checked_at":"2026-10-25T23:58:30.008Z","confidence":1,"stale":false},"citations":{"fact_id":"7727f9aa-3a30-41e3-8046-f7e80398d8f1","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-25T22:01:55.068Z","checked_at":"2026-10-26T03:03:29.557Z","confidence":1,"stale":false},"known_risks":{"fact_id":"6444bdd3-6c53-49b1-bb22-5bfb29af2511","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-25T23:58:30.023Z","confidence":1,"stale":false},"short_answer":{"fact_id":"31dc24d8-7dc4-4548-97a0-545f1a5bafd3","source_url":"https://peptideindex.ai/methodology#short-answer","source_type":"reference","captured_at":"2026-10-25T00:14:44.418Z","checked_at":"2026-10-25T23:58:30.009Z","confidence":1,"stale":false,"label":"our assessment"},"evidence_grade":{"fact_id":"6c583541-b56e-405b-b240-c82a2764bc72","source_url":"https://peptideindex.ai/methodology#evidence-grade","source_type":"reference","captured_at":"2026-10-25T00:14:45.193Z","checked_at":"2026-10-25T23:58:30.017Z","confidence":1,"stale":false,"label":"our assessment"},"open_questions":{"fact_id":"8f7fa321-da14-46fd-a9b5-41e8fdc47925","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-25T23:58:30.024Z","confidence":1,"stale":false},"section_routes":{"fact_id":"a5c52f17-922e-4018-9740-58bce3c1a00d","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-25T23:58:30.029Z","confidence":1,"stale":false},"regulatory_as_of":{"fact_id":"e7c55e46-6d99-4de0-9e85-d3de6e6fd532","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-25T22:01:55.068Z","checked_at":"2026-10-25T23:58:30.011Z","confidence":1,"stale":false},"section_channels":{"fact_id":"07eacd3e-c6ca-4f10-b727-d188e1b634b8","source_url":"https://pubmed.ncbi.nlm.nih.gov/42395176/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:57:40.541Z","checked_at":"2026-10-26T03:03:29.528Z","confidence":1,"stale":false},"section_evidence":{"fact_id":"15999eb0-6e0d-4157-a46e-6d223bbd8bda","source_url":"https://pubmed.ncbi.nlm.nih.gov/20130113/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:57:39.728Z","checked_at":"2026-10-26T03:03:29.517Z","confidence":1,"stale":false},"regulatory_status":{"fact_id":"9ac6bfc7-490f-4c86-bf96-e20f4ec1ad8f","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-25T23:58:30.000Z","confidence":1,"stale":false},"section_what_it_is":{"fact_id":"6c4b57d3-7bc3-4c7f-80bc-031fc90550ab","source_url":"https://pubmed.ncbi.nlm.nih.gov/20130113/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:57:39.728Z","checked_at":"2026-10-25T23:58:30.025Z","confidence":1,"stale":false},"section_is_it_legal":{"fact_id":"90cf6992-9007-429f-81f3-1a0c9a9efab1","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-25T23:58:30.005Z","confidence":1,"stale":false},"unofficial_channels":{"fact_id":"812d16fa-6ac0-4d95-88ce-40317287d75a","source_url":"https://pubmed.ncbi.nlm.nih.gov/42395176/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:57:40.541Z","checked_at":"2026-10-25T23:58:30.032Z","confidence":1,"stale":false}},"citationsBySection":{"known_risks":[{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":18,"title":"MGF in human prostate cancer tissue and cells, lab study, 2010","url":"https://pubmed.ncbi.nlm.nih.gov/20564425/"},{"n":21,"title":"Review: performance peptides that act on growth hormone and IGF-1, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"}],"open_questions":[{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":11,"title":"The MGF E domain in sheep after a heart attack, 2008","url":"https://pubmed.ncbi.nlm.nih.gov/17581790/"},{"n":13,"title":"MGF in injured mouse muscle, 2019","url":"https://pubmed.ncbi.nlm.nih.gov/31164836/"},{"n":16,"title":"The MGF peptide showed no effect on muscle cells in the lab, 2014","url":"https://pubmed.ncbi.nlm.nih.gov/24253050/"},{"n":20,"title":"Minireview: mechano growth factor and the IGF-1 gene, 2010","url":"https://pubmed.ncbi.nlm.nih.gov/20130113/"},{"n":18,"title":"MGF in human prostate cancer tissue and cells, lab study, 2010","url":"https://pubmed.ncbi.nlm.nih.gov/20564425/"},{"n":21,"title":"Review: performance peptides that act on growth hormone and IGF-1, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":4,"title":"FDA: notice of the next Pharmacy Compounding Advisory Committee meeting, no date posted","url":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee"}],"section_routes":[{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":2,"title":"FDA: categories of bulk drug substances nominated under section 503A, list updated 14 May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":5,"title":"FDA warning letter to a compounding pharmacy, 1 April 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"},{"n":4,"title":"FDA: notice of the next Pharmacy Compounding Advisory Committee meeting, no date posted","url":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee"}],"section_channels":[{"n":21,"title":"Review: performance peptides that act on growth hormone and IGF-1, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":7,"title":"FDA warning letter to a seller of research-use peptides, 24 August 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026"},{"n":5,"title":"FDA warning letter to a compounding pharmacy, 1 April 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"},{"n":6,"title":"US Department of Justice: a compounding pharmacy pleads guilty to distributing unapproved drugs, 29 October 2020","url":"https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"section_evidence":[{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":11,"title":"The MGF E domain in sheep after a heart attack, 2008","url":"https://pubmed.ncbi.nlm.nih.gov/17581790/"},{"n":12,"title":"A lab-made MGF E-domain peptide in mice after a heart attack, 2014","url":"https://pubmed.ncbi.nlm.nih.gov/25606570/"},{"n":13,"title":"MGF in injured mouse muscle, 2019","url":"https://pubmed.ncbi.nlm.nih.gov/31164836/"},{"n":14,"title":"A lab-made MGF E peptide on injured rat Achilles tendon, 2016","url":"https://pubmed.ncbi.nlm.nih.gov/27334712/"},{"n":15,"title":"An MGF gene in mice with an ALS-like disease, 2009","url":"https://pubmed.ncbi.nlm.nih.gov/19038252/"},{"n":16,"title":"The MGF peptide showed no effect on muscle cells in the lab, 2014","url":"https://pubmed.ncbi.nlm.nih.gov/24253050/"},{"n":17,"title":"Full-length MGF and short MGF peptides at the IGF-1 receptor, lab study, 2016","url":"https://pubmed.ncbi.nlm.nih.gov/26991004/"},{"n":20,"title":"Minireview: mechano growth factor and the IGF-1 gene, 2010","url":"https://pubmed.ncbi.nlm.nih.gov/20130113/"},{"n":21,"title":"Review: performance peptides that act on growth hormone and IGF-1, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"}],"section_what_it_is":[{"n":21,"title":"Review: performance peptides that act on growth hormone and IGF-1, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":20,"title":"Minireview: mechano growth factor and the IGF-1 gene, 2010","url":"https://pubmed.ncbi.nlm.nih.gov/20130113/"},{"n":16,"title":"The MGF peptide showed no effect on muscle cells in the lab, 2014","url":"https://pubmed.ncbi.nlm.nih.gov/24253050/"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":2,"title":"FDA: categories of bulk drug substances nominated under section 503A, list updated 14 May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":19,"title":"An MGF variant found in seized vials, lab study, 2017","url":"https://pubmed.ncbi.nlm.nih.gov/28035768/"}],"section_is_it_legal":[{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":2,"title":"FDA: categories of bulk drug substances nominated under section 503A, list updated 14 May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":3,"title":"FDA: bulk drug substances used in compounding under section 503A","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"n":8,"title":"McDermott Will & Schulte: what the July 2026 committee votes on peptides mean","url":"https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/"},{"n":9,"title":"Goodwin: FDA signals a possible change in its stance on compounding some peptides","url":"https://www.goodwinlaw.com/en/insights/blogs/2026/05/fda-signals-potentially-evolving-stance-toward-compounding-of-certain-peptides"},{"n":4,"title":"FDA: notice of the next Pharmacy Compounding Advisory Committee meeting, no date posted","url":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee"},{"n":22,"title":"RAPS: FDA considers adding a dozen peptides to its compounding list","url":"https://www.raps.org/resource/fda-considers-adding-a-dozen-peptides-to-its-bulk-drug-compounding-list.html"},{"n":23,"title":"Pharmacy Times: a pharmacist on what the peptide category change means, 4 June 2026","url":"https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means"},{"n":5,"title":"FDA warning letter to a compounding pharmacy, 1 April 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"}]},"channelsOpener":"This section describes what happens and is not a recommendation.","sources":["https://clinicaltrials.gov/api/v2/studies?query.intr=PEG-MGF+OR+pegylated+mechano+growth+factor&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","https://peptideindex.ai/methodology#evidence-grade","https://peptideindex.ai/methodology#short-answer","https://pubmed.ncbi.nlm.nih.gov/20130113/","https://pubmed.ncbi.nlm.nih.gov/42395176/","https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","https://www.fda.gov/media/94155/download"],"verified_at":"2026-10-26T03:03:29.557Z","published_at":"2026-10-26T03:03:31.088Z","parent":null,"children":[],"snapshots":{"trials":{"snapshot_at":"2026-10-25T23:58:35.856Z","stale":false,"notice":"A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record."}}}